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Abstract 
Objectives: Screening for cervical intraepithelial neoplasia (CIN) in HIV-infected women is 
essential to prevent invasive cervical cancer. Visual inspection with acetic acid (VIA) and HPV 
DNA testing have been proposed as alternatives to traditional cytology (or Papanicolaou [Pap] 
smears) screening programs. This meta-analysis provides pooled data on test performance (i.e., 
sensitivity, specificity, positive predictive value, and negative predictive value) of Pap, VIA, and 
HPV DNA testing with the Hybrid Capture II in HIV-infected women for diagnosing CIN2 or 
worse (CIN2+).  
Methods: A meta-analysis of cervical cancer screening test performance for HIV-infected 
women was conducted following the PRISMA guidelines using PubMed and EMBASE 
databases. Relevant data were extracted from the articles and analyzed using STATA 13.  
Results: Six studies met the inclusion criteria and were selected for analysis. The pooled 
sensitivity of HPV DNA testing was 86.9% (95% CI, 58.3%-97.0%), VIA was 77.6% (95% CI, 
73.5%-81.1%), Pap (at a low-grade squamous intraepithelial lesion [LSIL] threshold) 72.8% 
(95% CI, 41.1%-91.2%) and Pap (at a high-grade SIL [HSIL] threshold) 34.2% (95% CI, 8.7%-
74.0%). The pooled specificities were 60.2% (95% CI, 40%-77.5%) for HPV DNA testing, 
73.4% (95% CI, 50.5%-88.2%) for VIA, 72.9% (95% CI, 31.6%-94.0%) for Pap (LSIL 
threshold) and 94.5% (95% CI, 78.0%-98.8%) for Pap (HSIL threshold). 
Conclusions:  HPV DNA screening is a highly sensitive screening technique for HIV-infected 
women; however, there are still many barriers to its implementation in low-resource settings. 
VIA-based screening programs are a feasible alternative for HIV-infected women until the 
required resources (monetary resources and laboratory infrastructure) are committed for HPV 
DNA based screening programs.  
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Background 
Cervical cancer rates are decreasing in many western countries because there is now a 
clear understanding of the natural history of the disease,
1
 which has allowed for development of 
effective prevention and treatment strategies.
2
 Persistent high risk human papillomavirus (HPV)  
is well established as the inciting etiologic agent  in the vast majority of pre-invasive cervical 
cancers, (also referred to as cervical intraepithelial neoplasia [CIN]) and invasive cervical 
cancers.
1
 Approximately 5% of women with persistent, high-risk HPV infections will develop 
CIN grade 3 within a 10 year period.
3
  National screening programs implemented in western 
countries detect early stage, pre-invasive disease (CIN grades 1, 2, and 3), preventing its 
progression to invasive cancer.
4
 In the United States, for example, the age standardized incidence 
of cervical cancer has declined from 10.7 per 100,000 in 1990 (when organized Pap screening 
programs were introduced)
5
 to 6.7 per 100,000 in 2010.
6
  However, in regions without national 
screening programs, such as in sub-Saharan Africa, the rates of cervical cancer are still 
increasing.
7
 Globally, there were an estimated 275,000 deaths from cervical cancer in 2008 and 
an estimated 529,000 new cases.
2
 The majority (80%) of these deaths occurred in developing 
countries that also have the highest HIV rates.
7
  
The Papanicolaou (Pap) smear is the traditional cytology screening test for secondary 
prevention of cervical cancer in high-resource countries. Cytology screening is used to detect 
SIL and has been extremely successful in reducing rates of cervical cancer. A 60% to 90% 
reduction was seen within three years of implementation in high-resource countries.
8
 There are, 
however, several drawbacks to Pap screening that make it difficult to implement in low-resource 
settings. First, because of the need for sophisticated equipment and highly trained lab personal, 
the cost of Pap based screening programs is often prohibitive.
4,9
 Second, a single round of Pap 
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screening has a low sensitivity (50%-70%), and repeat smears over the course of a woman’s 
lifetime are necessary to improve the performance of the test. Finally, women also need to come 
back into the clinic to receive their results, increasing the likelihood of loss to follow-up.
4,9
 
Visual inspection with acetic acid (VIA) had been proposed as an alternative to 
traditional cytology screening programs.
10,11
 VIA is a direct visual inspection technique in which 
the practitioner applies 3–5% dilute acetic acid to the cervix and then examines the cervix using 
a bright light. The identification of aceto-white areas on the cervix is considered a positive screen 
because these areas are associated with CIN. An advantage of VIA, particularly in low-resources 
settings, is that the screening results are immediate and women can be treated for CIN during the 
same visit as the screening. This is known as the “screen-and-treat” approach. It minimizes the 
risk of loss to follow-up after a positive screen that occurs with other screening methods such as 
cytology or HPV DNA testing. It is also inexpensive,
11,12
 as the materials needed for the 
screening process are easy to obtain even in low-resource settings and VIA does not require any 
laboratory equipment.
13,14
 However, the drawback to VIA is that both the sensitivity and 
specificity are lower that of HPV DNA testing.
13
    
HPV DNA testing is another alternative to cytology screening for CIN because of its 
sensitivity and specificity are, higher than both Pap and VIA.
15
 It also has the advantage of a 
more simple sampling procedure that can be performed by either a practitioner or the women 
herself.
16,17
 The self-collected samples can reduce the number of visits required for testing. The 
one disadvantage to the self-collect sample is that it has been shown to have more variability in 
its sensitivity than the practitioner collected samples.
8
 However, HPV DNA testing in general 
requires higher technical abilities than VIA screening including the need for polymerase chain 
reaction (PCR) equipment and staff trained in the equipment, making it difficult to implement in 
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low-resource settings.
15
 HPV DNA testing is also more expensive than VIA which can be a 
limiting factor in low-resource settings where there are competing health priorities and limited 
funding.
8
  
Cervical cancer screening programs are needed to prevent cervical cancer among all 
women. Screening programs are particularly important among high-risk populations such as 
HIV-infected women. HIV-infected women are at an increased risk for sexually transmitted 
diseases,
7,18
 including HPV. This increased risk has been found in HIV-infected women with 
both low and high CD4 counts.
19,20
 HIV-infected women are also less likely to clear an HPV 
infection,  and more likely to have a persistent high-risk infection that progresses to pre-invasive 
or invasive cancer.
7
  
The relative risk of HPV for HIV-infected compared to HIV-negative women does not 
vary greatly between populations but the risk of cervical cancer does because of the inequitable 
access and effectiveness of screening strategies, particularly in developing countries
21
 In Africa, 
cervical cancer is the leading cause of cancer death for women. Within Africa, women in East 
and West Africa have 5 times the mortality rate from cervical cancer as women in North 
Africa.
22
 Access to effective cervical cancer screening programs, particularly for high risk 
women (including HIV-infected women) has a great impact on the differences in cervical cancer 
burden between countries.   
The cervical cancer health burden in HIV-infected women has also been impacted by the 
introduction of anti-retroviral medications. These life-saving medications have enabled HIV-
infected women to live longer but because of the longer life span, they have also increased the 
risk of HIV-associated malignances, including cervical cancer.
23,24
  Early diagnosis and 
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treatment of CIN through screening programs for HIV-infected women is essential in preventing 
morbidity and mortality from cervical cancer. 
Significance:  
Cytology screening programs have been shown to be effective in reducing the rates of 
cervical cancer in the developed world. However, traditional cytology screening programs are 
difficult to implement in low-resource settings that have the highest burden of cervical cancer 
and co-infection with HIV. 
25
 In order to reduce the burden of cervical cancer in HIV-infected 
women, effective strategies that can be implemented in developing countries
26
 need to be 
studied. Visual inspection with acetic acid and HPV DNA testing have been proposed as 
alternatives to cytology screening.
13,25
 A meta-analysis of screening test performance for these 
alternative tests in HIV-infected women has not been published and would fill a gap in the 
literature on cervical cancer screening.  
We conducted a meta-analysis of cervical cancer screening test performance for HIV-
infected women following the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines. We used the PRISMA 27 steps and flow diagram (Figure 1) to 
organize the meta-analysis.
27
  
Methods 
Objectives 
What is the test performance of Pap, VIA, and HPV DNA testing with the Hybrid 
Capture II (HC2) in HIV-infected women? What is the test sensitivity and specificity for 
diagnosing CIN2+?   
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Data Sources 
We searched PubMed and EMBASE databases (2003 to present) for cervical cancer 
prevention studies that address the use of Pap, VIA, and HPV DNA testing in HIV-infected 
women. The last search was run on 8 August 2013. We used the following search terms for both 
searches: HIV; cervical cancer; cervical intraepithelial neoplasia; CIN; HPV; human 
papillomavirus; screening; VIA; visual inspection with acetic acid; DNA; Pap; Pap smear; 
Papanicolaou test; prevention. Additionally, the bibliographies of relevant articles were reviewed 
to determine if there were any other applicable studies that need to be included in the analysis. 
The results from each search including the date, time, and database searched were recorded using 
Microsoft Excel in order to ensure reproducibility of the results.  
Eligibility Criteria 
Studies were selected using the following inclusion criteria: 1) participating women were 
HIV-infected, 2) screening studies included cross-sectional, cohort, and experimental studies for 
Pap smear, VIA, and HPV DNA testing with HC2, 3) the gold standard for screening test 
statistic performance was histologically-proven disease, 4) the outcome measure was CIN2+. 
Studies were excluded if they were qualitative or participating women had a hysterectomy, 
previously tested positive for CIN2+, or previously had cervical cancer. Study validity was 
considered in the review based on the selection process for participants. Studies were reviewed 
and excluded by title and by abstract. Full studies were then selected for inclusion based on the 
above inclusion and exclusion criteria. Study exclusion and inclusion was then checked by a 
second independent reviewer to reduce reviewer bias.  
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Data Extraction 
We created a data extraction sheet using Microsoft Excel specifically designed for this 
meta-analysis. Abstracted data included the characteristics of study participants, screening type, 
number of participants, outcome measure (severity of disease), gold standard for measuring test 
performance, the sensitivity and specificity with accompanying 95% confidence intervals and the 
true positive, true negative, false positive, and false negative for each screening test.  
Statistical Analysis 
The data were analyzed using STATA v13.0 (College Station, Texas) statistical software 
and graphed using Microsoft Excel (Redmond, Washington). The true positive, true negative, 
false positive, and false negative for each screening test by study was entered into STATA and 
the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) 
for each of the studies was calculated. The results were then converted to the logit scale and 
pooled test statistics were calculated using metan, a meta-analysis procedure in STATA. The 
output was then back transformed to the probability scale. The heterogeneity was tested using 
Cochran’s Q test (p≤ 0.05) and the effect of heterogeneity was calculated using the I2 index, 
which indicates the percentage of variation between studies that is attributed to heterogeneity. 
Substantial heterogeneity was defined I
2 ≥ 75%.28 If heterogeneity was identified, a random 
effects model was chosen for the meta-analysis. Forest plots of the sensitivity and specificity for 
each screening test were generated using Microsoft Excel.  
Results 
Study Selection 
The systematic search of the PubMed and EMBASE databases resulted in a total of 715 
articles. Upon review of the references for the studies, an additional 41 articles were included for 
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review. 50 duplicated articles were eliminated. 659 articles were eliminated by title and abstract 
because they did not meet the eligibility criteria for the meta-analysis. An additional 34 articles 
were eliminated by full text with 6 studies meeting the inclusion criteria (5 from the database 
search and 1 from the references)
29–34
 (Figure 1).  
Figure 1. PRISMA Flow Diagram
 
 
Study Characteristics  
For each of the 6 eligible studies, study characteristics are included in Table 1. There 
were 4 cross-sectional and 2 cohort studies conducted in 5 different countries. 5 of the studies 
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addressed the test performance for Pap, 4 for VIA, and 4 for HPV DNA testing with HC2. 
Individual study size ranged from 83 women in the smallest pilot study to 1128 women in the 
largest cross-sectional study with a total of 2,804 women participating in cervical cancer 
screening (2503 women tested by PAP, 2,507 by VIA and 2,449 by HPV DNA testing with 
HC2). All women in included in the studies were HIV-infected and received at least one of the 
three screening strategies. The gold standard for all of the studies was histology. 
Table 1. Study Characteristics by Screening Test 
  
Title Author 
Year 
Published Country 
Study 
Design 
Inclusion Criteria and 
Study Population Exclusion criteria 
Study 
Size 
Gold 
Standard 
Disease 
Threshold 
Screening Test: PAP 
Validation of 
cervical cancer 
screening methods 
in HIV positive 
women from 
Johannesburg South 
Africa Firnhaber et al. 2013 
South 
Africa 
cross-
sectional 
Eligible following 
treatment of 
symptomatic STD, if 
menstruating at 
study enrollment 
asked to return 
within one to two 
weeks , HIV-positive 
pregnant, previously 
undergone a 
hysterectomy/treatme
nt for cervical 
neoplasia or cancer, 
severely ill, signs 
and/or symptoms 
suggestive of a STD 941 histology CIN2+ 
Screening of cervical 
neoplasia in HIV-
infected women in 
India. Joshi et al. 2013 India 
cross-
sectional 
HIV-infected women, 
21 and 60 years, no 
debilitating illness, 
not pregnant at 
recruitment, intact 
uterus with no 
prolapse, and no 
previous history of 
cervical neoplasia   1081 histology CIN2+ 
Comparison of 
conventional 
cervical cytology 
versus visual 
inspection with 
acetic acid among 
HIV-infected 
women in Western 
Kenya Mabeya et al. 2012 Kenya 
cross-
sectional 
Female, age 15–49 
years, documented 
HIV infection, 
healthy, no 
debilitating disease 
Current pregnancy or 
pregnancy in the last 6 
months, history of or 
treatment for cervical 
cancer, total 
hysterectomy, 
dilatation and 
curettage in the last 6 
months, current 
mucopurulent 
discharge, active 
vaginal bleeding, and 
diagnosis of STI in the 
last 3 weeks 135 histology CIN2+ 
Comparison of 
visual inspection 
with acetic acid and 
cervical cytology to 
detect high-grade 
cervical neoplasia 
among HIV- infected 
Sahasrabuddhe 
et al. 2012 India 
cohort 
study 
consenting 
nonpregnant and 
previously 
unscreened HIV-
infected women 
were enrolled in this 
study   266 histology CIN2+ 
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women in India 
HPV Prevalence and 
Cervical 
Intraepithelial 
Neoplasia among 
HIV-infected 
Women in Yunnan 
Province, China : A 
Pilot Study Zhang et al. 2012 China 
cross-
sectional 
HIV-positive, 
negative urine 
pregnancy test, no 
debilitating illness 
that may preclude a 
pelvic examination, 
no prior history of 
screening or 
treatment for 
cervical neoplasia, 
and hysterectomy   80 
colposcopy
/histology CIN2+ 
Screening Test: VIA 
Validation of 
cervical cancer 
screening methods 
in HIV positive 
women from 
Johannesburg South 
Africa Firnhaber et al. 2013 
South 
Africa 
cross-
sectional 
Eligible following 
treatment of 
symptomatic STD, if 
menstruating at 
study enrollment 
asked to return 
within one to two 
weeks , HIV-positive 
pregnant, previously 
undergone a 
hysterectomy/treatme
nt for cervical 
neoplasia or cancer, 
severely ill, signs 
and/or symptoms 
suggestive of a STD 941 histology CIN2+ 
Screening of cervical 
neoplasia in HIV-
infected women in 
India. Joshi et al. 2013 India 
cross-
sectional 
HIV-infected women, 
21 and 60 years, no 
debilitating illness, 
not pregnant at 
recruitment, intact 
uterus with no 
prolapse, and no 
previous history of 
cervical neoplasia   1128 histology CIN2+ 
Comparison of 
conventional 
cervical cytology 
versus visual 
inspection with 
acetic acid among 
HIV-infected 
women in Western 
Kenya Mabeya et al. 2012 Kenya 
cross-
sectional 
Female, age 15–49 
years, documented 
HIV infection, 
healthy, no 
debilitating disease 
Current pregnancy or 
pregnancy in the last 6 
months, history of or 
treatment for cervical 
cancer, total 
hysterectomy, 
dilatation and 
curettage in the last 6 
months, current 
mucopurulent 
discharge, active 
vaginal bleeding, and 
diagnosis of STI in the 
last 3 weeks 135 histology CIN2+ 
Comparison of 
visual inspection 
with acetic acid and 
cervical cytology to 
detect high-grade 
cervical neoplasia 
among HIV- infected 
women in India 
Sahasrabuddhe 
et al. 2012 India 
cohort 
study 
consenting 
nonpregnant and 
previously 
unscreened HIV-
infected women 
were enrolled in this 
study   303 histology CIN2+ 
Screening Test: HC2 HPV DNA  
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Validation of 
cervical cancer 
screening methods 
in HIV positive 
women from 
Johannesburg South 
Africa Firnhaber et al. 2013 
South 
Africa 
cross-
sectional 
Eligible following 
treatment of 
symptomatic STD, if 
menstruating at 
study enrollment 
asked to return 
within one to two 
weeks , HIV-positive 
pregnant, previously 
undergone a 
hysterectomy/treatme
nt for cervical 
neoplasia or cancer, 
severely ill, signs 
and/or symptoms 
suggestive of a STD 941 histology CIN2+ 
Screening of cervical 
neoplasia in HIV-
infected women in 
India. Joshi et al. 2013 India 
cross-
sectional 
HIV-infected women, 
21 and 60 years, no 
debilitating illness, 
not pregnant at 
recruitment, intact 
uterus with no 
prolapse, and no 
previous history of 
cervical neoplasia   1128 histology CIN2+ 
Prevalence and 
predictors of 
colposcopic-
histopathologically 
confirmed cervical 
intraepithelial 
neoplasia in HIV-
infected women in 
India. 
Sahasrabuddhe 
et al. 2010 India 
cohort 
study 
HIV-positive, 
negative urine 
pregnancy test, no 
debilitating illness 
that may preclude a 
pelvic examination, 
no prior history of 
screening or 
treatment for 
cervical neoplasia, 
and no prior 
hysterectomy 
pregnancy or prior 
hysterectomy 297 histology CIN2+ 
HPV Prevalence and 
Cervical 
Intraepithelial 
Neoplasia among 
HIV-infected 
Women in Yunnan 
Province, China : A 
Pilot Study Zhang et al. 2012 China 
cross-
sectional 
HIV-positive, 
negative urine 
pregnancy test, no 
debilitating illness 
that may preclude a 
pelvic examination, 
no prior history of 
screening or 
treatment for 
cervical neoplasia, 
and hysterectomy   83 
colposcopy
/histology CIN2+ 
 
Heterogeneity Test:  
 Heterogeneity was detected between studies in the meta-analysis for all of the screening 
tests (I
2 ≥ 75% and p ≤ 0.05) except for VIA. In the case of VIA, homogeneity was found for test 
sensitivity (I
2 
= 0.0% and p = 0.65) but not for test specificity (I
2 
= 98.2% and p = 0.0). 
Therefore, a random effects model was used to calculate pooled test statistics for this meta-
analysis.  
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Accuracy of Screening Tests: 
 The accuracy of the screening tests for CIN2+ detection in HIV-infected women was 
assessed using the sensitivity and specificity. The individual study results are presented in Table 
2 with their respective 95% confidence intervals. Pooled estimates of performance were 
calculated for each screening test. The HPV DNA test had the highest pooled sensitivity at 
86.9% (95% CI, 58.3%-97.0%) and VIA has the second highest pooled sensitivity at 77.6% 
(95% CI, 73.5%-81.1%). Pap sensitivity was measured at two thresholds: a low grade squamous 
intraepithelial lesion (LSIL) cutoff and a high grade squamous intraepithelial lesion (HSIL) 
cutoff. The pooled sensitivity for Pap was higher using the LSIL cutoff (72.8%; 95% CI, 41.1%-
91.2%) than the HSIL cutoff (34.2%; 95% CI, 8.7%-74.0%) (Figure 2 – Forest Plots: Sensitivity 
for Screening Tests for CIN2+).  
The HPV DNA and VIA screening tests had pooled specificities of 60.2% (95% CI, 40%-
77.5%) and 73.4% (95% CI, 50.5%-88.2%), respectively. For Pap, the pooled specificity using 
the LSIL cutoff and the HSIL cutoff were 72.9% (95% CI, 31.6%-94.0%) and 94.5% (95% CI, 
78.0%-98.8%), respectively (Figure 3 – Forest Plots: Specificity for Screening Tests for CIN2+).  
The HPV DNA and VIA screening tests had pooled PPV of 24.5% (95% CI, 2.5%-
42.5%) and 40.8% (95% CI, 31.0%-51.3%), respectively. The pooled PPV for Pap using an 
LSIL cutoff and Pap using an HSIL cutoff were 35.4% (95% CI, 29.9%-41.4%) and 58.9% (95% 
CI, 49.4%-67.8%), respectively. The pooled NPV were 96.6% (95% CI, 89.1%-99.0%) for HPV 
DNA testing, 93.2% (95% CI, 77.8%-98.1%) for VIA, 92.9% (95% CI, 82.4%-97.3%) for Pap 
using an LSIL cutoff and 88.4% (95% CI, 76.2%-94.7%) for Pap using an HSIL cutoff (Table 2. 
Cervical Cancer Screening Test Performance). 
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Figure 2. Forest Plots 
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Discussion 
Based on this meta-analysis of test performance of Pap, VIA, and HPV among HIV-
infected women, HPV testing appears to have the highest sensitivity of 86.9% (95% CI, 58.3%-
97.0%).  This is ideal for women at high risk of pre-invasive and invasive cervical cancer (e.g., 
Table 2. Cervical Cancer Screening Test Performance 
  
Author 
Screening 
Type 
Sensitivity (95% 
confidence interval) 
Specificity (95% 
confidence interval) 
PPV (95% confidence 
interval) 
NPV (95% confidence 
interval) 
Firnhaber et al. PAP - LSIL 97.4% (94.9%-98.7%) 21.4% (18.4%-24.8) 37.8% (34.5%-41.3%) 94.4% (89.2%-97.2%) 
Joshi et al. PAP - LSIL 52.0% (38.3%-65.3%) 96.0% (94.6%-97.1%) 38.8% (28.0%-50.9%) 97.6% (96.5%-98.4%) 
Mabeya et al. PAP - LSIL 52.5% (37.2%-67.3%) 66.3% (56.3%-75.1%) 39.6% (27.5%-53.2%) 76.8% (66.5%-84.7%) 
Sahasrabuddhe 
et al. PAP - LSIL 60.5% (45.4%-73.8%) 64.6% (58.1%-70.6%) 24.8% (17.4%-33.9%) 89.4% (83.7%-93.3%) 
Zhang et al. PAP - LSIL 66.7% (33.3%-88.8%) 85.9% (75.8%-92.3%) 37.5% (17.9%-62.3%) 95.3% (86.5%-98.5%) 
Total PAP LSIL   72.8% (41.1%-91.2%) 72.9% (31.6%-94.0%) 35.4% (29.9%-41.4%) 92.9% (82.4%-97.3%) 
Firnhaber et al. PAP - HSIL 78.4% (73.5%-82.6%) 78.8% (75.4%-81.8%) 64.5% (59.5%-69.1%) 88.1% (85.2%-90.5%) 
Joshi et al. PAP - HSIL 22.0% (12.6%-35.5%) 99.2% (98.5%-99.6%) 57.9% (35.6%-77.4%) 96.3% (95.0%-97.3%) 
Mabeya et al. PAP - HSIL 20.0% (10.3%-35.2%) 89.5% (81.5%-94.2%) 44.4% (24.0%-67.0%) 72.6% (63.9%-80.0%) 
Sahasrabuddhe 
et al. PAP - HSIL 20.9% (11.3%-35.6%) 96.0% (92.4%-97.9%) 50.0% (24.0%-67.0%) 86.3% (81.4%-90.0%) 
Total PAP HSIL   34.2% (8.7%-74.0%) 94.5% (78.0%-98.8%) 58.9% (49.4%-67.8%) 88.4% (76.2%-94.7%) 
Akinwuntan et 
al. VIA 76.2% (54.0%-89.7%) 83.2% (77.0%-87.9%) 34.0% (22.0%-48.5%) 96.8% (92.6%-98.7%) 
Firnhaber et al. VIA 77.7% (72.8%-82.0%) 59.6% (55.7%-63.3%) 48.6% (44.2%-53.0%) 84.5% (80.8%-87.6%) 
Joshi et al. VIA 81.7% (69.8%-89.5%) 88.8% (86.7%-90.5%) 29.0% (22.7%-36.3%) 98.9% (97.9%-99.4%) 
Mabeya et al. VIA 69.6% (54.9%-81.1%) 51.0% (41.4%-60.4%) 38.6% (28.7%-49.3%) 79.1% (67.7%-87.2%) 
Sahasrabuddhe 
et al. VIA 80% (66.7%-88.9%) 82.6% (77.4%-86.8%) 47.6% (37.2%-58.2%) 95.4% (91.7%-97.5%) 
Total VIA   77.6% (73.5%-81.1%) 73.4% (50.5%-88.2%) 40.8% (31.0%-51.3%) 93.2% (77.8%-98.1%) 
Firnhaber et al. 
HC2 HPV 
DNA 93.5% (90.2%-95.8%) 43.9% (40.1%-47.8%) 45% (41.2%-48.9%) 93.3% (89.8%-95.6%) 
Joshi et al. 
HC2 HPV 
DNA 95% (85.6%-98.4%) 77.4% (75%-79.8%) 19.1% (15.1%-24%) 99.6% (98.9%-99.9%) 
Sahasrabuddhe 
et al. 
HC2 HPV 
DNA 56.3% (42.1%-69.5%) 61% (54.8%-66%) 21.8% (15.4%-29.9%) 87.9% (82.1%-92.0%) 
Zhang et al. 
HC2 HPV 
DNA 85.7% (41.9%-98%) 55.3% (44%-66%) 15% (6.9%-29.6%) 97.7% (85.3%-99.7%) 
Total HC2 HPV DNA 86.9% (58.3%-97%) 60.2% (40%-77.5%) 24.5% (12.5%-42.5%) 96.6% (89.1%-99.0%) 
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HIV-infected women) because HIV-infected women are more likely to have rapid progression of 
cancers
7,18
 and a missed case could result in serious morbidity or mortality. The test also has 
specificity of 60.2% (95% CI, 40%-77.5%), a PPV of 24.5% (95% CI, 12.5%-42.5%) , and a 
NPV of 96.6% (95% CI, 89.1%-99.0%) . Despite its relatively favorable performance profile, 
several important barriers to wide-scale implementation remain, particularly in low-resources 
settings.  
 First, HPV DNA testing with HC2 is more expensive than VIA.
8
 According to a cost 
analysis of cervical cancer screening techniques in South Africa by Goldie et al.
35
 a single 
lifetime screening with HPV DNA testing (HC2) was associated with a cost of $118/years of life 
saved (YLS). A single lifetime screening program with VIA on the other hand was less 
expensive than not implementing a screening program. It may be possible to reduce the cost of 
HPV DNA testing if patient collected samples can be used instead of clinician collected samples. 
This reduced the cost effectiveness ratio for a single lifetime screening for HPV DNA testing to 
$26/YLS compared to no screening.
35
 In addition, new rapid HPV DNA tests such as careHPV
TM
 
have the potential to decrease the screening cost to $50/YLS
36
 for a single lifetime visit. 
Second, HPV DNA testing with HC2 is technically complex.
15
 Running HC2 HPV DNA 
test, detecting 13 high risk HPV genotypes with single amplification technology, requires 
sophisticated laboratories and training that may not be available in low-resources settings.
37
 To 
address this issue, the careHPV
TM
 screening test was developed as an alternative to HPV DNA 
testing with HC2 for low-resource settings.
37,38
 It does not require refrigeration of the reagent, 
can be run by a healthcare worker with limited training, and only takes two and half hours to run 
the results.
37
 The implementation of screening programs using careHPV
TM
 may make national 
HPV screening programs a feasible option in low-resource settings.  
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 Finally, HPV DNA testing is logistically complex, requiring multiple visits and a 
diagnostic test. HPV DNA testing requires multiple visits to a health facility because there are no 
commercially available point-of-care HPV tests.
8
 In order to reduce the number of visits, 
researchers have looked into the efficacy of HPV DNA testing samples collected by the patient 
herself because the quality of the sample is less important in determining the sensitivity of HPV 
DNA testing than in cytology screening.
39
 A meta-analysis by Ogilvie et al.
40
 found that self-
collected samples for HPV DNA testing has similar accuracy (sensitivity of 74% and a 
specificity of 88%) to provider collected samples;
28
 however, there is limited data  on self-
collection in HIV-infected women. 
If HPV DNA testing is used as the primary screening technique, a diagnostic test is 
essential to reduce overtreatment because of its modest specificity  60.2% (95%, CI 40%-
77.5%), likely due to the large number of HIV-infected women that are infected with HPV DNA 
but do not exhibit lesions.
39
 Colposcopy is recommended for all positive cases; however, due to 
the higher number of false positives with HPV DNA screening, a PPV of only 24.5% (95%, 
CI12.5%-42.5%), the number of women sent for a diagnostic test would increase, increasing the 
cost and case load at colposcopy clinics.
41
 However, this meta-analysis demonstrated that HPV 
DNA testing has a high negative predictive value of 96.6% (95%, CI 89.1%-99.0%). Therefore, a 
HIV-infected woman that tests negative for HPV DNA is not likely to have cervical lesions and 
would not need follow-up diagnostic testing. HIV-infected women have a higher prevalence of 
HPV infection than HIV-negative  women, therefore, for HPV DNA testing to be used as a 
primary screening technique there need to be local resources and personnel to provide the 
additional diagnostics to confirm the presence of lesions in HPV-positive women.
42
 If no 
diagnostic test is available in a limited resource setting, triage tests with either VIA or Pap after 
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screening with HPV DNA testing has been proposed as an alternative,
42
 particularly if they can 
be done at the same visit. This could be an alternative to expensive diagnostic tests; however, 
additional research is needed on this topic for HIV-infected women.   
In many low-resource settings, VIA has been used to overcome the barriers associated 
with either cytology or HPV-based screening. For example prioritizing a screening test with high 
specificity rather than sensitivity would  reduce the cost associated with the diagnostic test
41
 and 
over-treatment, which may be associated with adverse pregnancy outcomes such as spontaneous 
abortion,
43
 pre-term delivery,
44,45
 and cervical stenosis.
45
 While Pap with a HSIL threshold had 
the highest specificity at 94.5% (95%, CI 78.0%-98.8%), Pap smear screening programs are 
difficult to implement in low-resource settings because of the resources and personal required.
4,9
 
In addition, studies have found high false negative rates when screening with cytology in HIV-
infected women.
39
 VIA has a higher specificity than HPV DNA testing (73.4% compared to 
60.2%) and a lower cost to implement, both in technical expertise and equipment.
8
 
 VIA can also be implemented using the screen-and-treat approach in which a women is 
screened and treated in the same visit without a confirmatory diagnostic test. This approach has 
already been implemented in several countries as an alternative to the traditional cervical 
screening method of conducting the screening test in the first visit and returning for a second 
visit for treatment.
46–49
 The screen-and-treat approach can reduce the number of visits required 
for screening and treatment and reduces the risk of loss to follow-up.
45
 It has also been 
determined to be safe in HIV-infected women
18,49
  and is a feasible screening option for HIV-
infected women in low-resource settings. Additional research could strengthen the argument for 
the use of the screen-and-treat approach in HIV-infected women because currently some studies 
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do not confirm their diagnosis with colposcopy directed biopsy
49,50
 and therefore, over treatment 
or missed cases cannot be determined. 
Strengths of the Study 
 This meta-analysis was conducted based on the PRISMA guidelines for meta-analyses 
and systematic reviews, reducing the risk of reporting bias in the results. All studies that met the 
inclusion and exclusion criteria for the review and had available data were included in the 
analysis. In addition, all efforts were made to contact the original authors of studies that were 
considered for inclusion but did not provide all of the necessary results in the published articles. 
Also, the pooled statistics were calculated taking into account variability across studies in 
screening test performance.   
Limitations of the study 
 One of the main limitations of the meta-analysis was that for the pooled test performance, 
the patient populations, sample size, and screening methods were not exactly the same. There 
was an age range in the populations from 18 through 65 years. The differences in screening test 
performance were not broken down by age group in all of the studies. Also, studies had different 
sample sizes ranging from 83 to 1,128 which affected the power of the individual studies and the 
may have reduced reliability of the smaller study test statistics. The pooled test statistics 
calculated in the meta-analysis may have then been affected by the resultant variation in 
reliability. Furthermore, the training and practitioner for the screening methods were not 
standardized across studies. This is relevant to the current meta-analysis because VIA has been 
shown to be more accurate when an experienced nurse or doctor is performing the procedure.
29
 
All of these differences may have led to the high level of heterogeneity between the studies. 
There may have also been positive bias in the studies due to the use of colposcopy directed 
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biopsy to perform histology as the gold standard.
51–53
 Colposcopy is not an exact test and may in 
fact miss the same CIN2+ lesions as the other screening tests for cervical cancer including those 
included in this meta-analysis, falsely increasing the sensitivity of the screening test.
53
 Therefore, 
the sensitivities reported in the meta-analysis may be higher than the true test sensitivities.   
Conclusion 
This meta-analysis demonstrates that HPV DNA testing with HC2 is highly sensitive 
(86.9%; 95% CI, 58.3%-97%) for HIV-infected women.  Because molecular testing is often 
more reliable, it is becoming the preferred global standard; however, there are still any barriers to 
implementing molecular screening programs in low-resources settings.  These include the 
relatively high cost of the test, a need for a well-established, modern national laboratory services, 
and the logistical difficulties of asking women to return for test results and/or for additional 
diagnostic testing and treatment. While countries work towards establishing more complex HPV-
based screening programs, VIA screening may be an acceptable, short-term alternative. The 
single-visit screen-and-treat approach is an important and attractive feature of VIA-based 
programs. VIA may also be easier to integrate into already existing HIV programs than HPV 
DNA testing because of the low cost and lack of technology required.
13,14
 This meta-analysis 
combines the existing literation on cervical cancer screening modalities for HIV-infected 
women, demonstrating the current gaps in this field of study.  
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